Innovimmune Biotherapeutics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 3

Innovimmune Biotherapeutics General Information

Description

Developer of novel oral small-molecule immunomodulatory drugs designed to treat cancer, autoimmune diseases, and chronic inflammation using AI-driven structure-guided drug design. The company develops proprietary New Chemical Entity immunotherapies utilizing AI-driven, structure-guided drug design to turn historically untargetable disease-causing proteins into viable druggable targets, enabling clients to access a pipeline in a molecule approach that advances single drug candidates across multiple therapeutic indications simultaneously

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • 75 Wall Street
  • New York, NY 10005
  • United States
+1 (718)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 75 Wall Street
  • New York, NY 10005
  • United States
+1 (718)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Innovimmune Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator Completed Generating Revenue
2. Grant 25-Jul-2014 Completed Generating Revenue
1. Grant 01-Jan-2011 $600K Completed Generating Revenue
To view Innovimmune Biotherapeutics’s complete valuation and funding history, request access »

Innovimmune Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel oral small-molecule immunomodulatory drugs designed to treat cancer, autoimmune diseases, and chronic
Biotechnology
New York, NY

Newton, MA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Innovimmune Biotherapeutics Competitors (72)

One of Innovimmune Biotherapeutics’s 72 competitors is Adiso Therapeutics, a Venture Capital-Backed company based in Newton, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adiso Therapeutics Venture Capital-Backed Newton, MA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Apogee Therapeutics Formerly VC-backed Waltham, MA
You’re viewing 5 of 72 competitors. Get the full list »

Innovimmune Biotherapeutics Patents

Innovimmune Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2696682-A2 Mif inhibitors and their uses Active 13-Apr-2011
EP-2696682-A4 Mif inhibitors and their uses Active 13-Apr-2011
EP-2696682-B1 Mif inhibitors and their uses Inactive 13-Apr-2011
EP-3354640-A2 Mif inhibitors and their uses Inactive 13-Apr-2011
EP-3354640-A3 Mif inhibitors and their uses Inactive 13-Apr-2011 C07D401/12
To view Innovimmune Biotherapeutics’s complete patent history, request access »

Innovimmune Biotherapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institute Of Allergy and Infectious Diseases Government
U.S. Department of Health and Human Services Government
Start-up NY Accelerator/Incubator Minority
To view Innovimmune Biotherapeutics’s complete investors history, request access »

Innovimmune Biotherapeutics FAQs

  • When was Innovimmune Biotherapeutics founded?

    Innovimmune Biotherapeutics was founded in 2010.

  • Where is Innovimmune Biotherapeutics headquartered?

    Innovimmune Biotherapeutics is headquartered in New York, NY.

  • What industry is Innovimmune Biotherapeutics in?

    Innovimmune Biotherapeutics’s primary industry is Biotechnology.

  • Is Innovimmune Biotherapeutics a private or public company?

    Innovimmune Biotherapeutics is a Private company.

  • What is Innovimmune Biotherapeutics’s current revenue?

    The current revenue for Innovimmune Biotherapeutics is .

  • Who are Innovimmune Biotherapeutics’s investors?

    National Institute Of Allergy and Infectious Diseases, U.S. Department of Health and Human Services, and Start-up NY have invested in Innovimmune Biotherapeutics.

  • Who are Innovimmune Biotherapeutics’s competitors?

    Adiso Therapeutics, CytomX Therapeutics, Sorrento Therapeutics, Adaptimmune Therapeutics, and Apogee Therapeutics are some of the 72 competitors of Innovimmune Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process